BPMC (Blueprint Medicines) Insider Ownership : 2.21 % (As of Apr. 14, 2025)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Blueprint Medicines's insider ownership is 2.21%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Blueprint Medicines's Institutional Ownership is 105.89%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Blueprint Medicines's Float Percentage Of Total Shares Outstanding is 88.84%.

Blueprint Medicines Insider Ownership Historical Data

The historical data trend for Blueprint Medicines's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Insider Ownership Chart

Blueprint Medicines Historical Data

The historical data trend for Blueprint Medicines can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Insider Ownership	2.20	2.23	2.20	2.18	2.17	2.16	2.14	2.13	2.11	2.21

Blueprint Medicines Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Executives

Jeffrey W. Albers	director, officer: CEO & President	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
L. Becker Hewes	officer: Chief Medical Officer	C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter	officer: Chief Scientific Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee	officer: Chief Commercial Officer	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi	officer: Chief Commercial Officer	45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain	officer: EVP and Chief Legal Officer	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel	officer: Principal FAO	BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus	officer: Chief People Officer	C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Fouad Namouni	officer: President, R and D	535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
Ariel Hurley	officer: Principal Accounting Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland	officer: Chief Business Officer	BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Christopher K. Murray	officer: SVP, Technical Operations	C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai	director	BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139